Pancreatic cancer MRI

Jump to navigation Jump to search

Pancreatic cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Pancreatic Cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

Diagnostic study of choice

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pancreatic cancer MRI On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pancreatic cancer MRI

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pancreatic cancer MRI

CDC on Pancreatic cancer MRI

Pancreatic cancer MRI in the news

Blogs on Pancreatic cancer MRI

Directions to Hospitals Treating Pancreatic cancer

Risk calculators and risk factors for Pancreatic cancer MRI

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aravind Reddy Kothagadi M.B.B.S[2]

Overview

MRI is considered when there is a diagnostic difficulty even after performing a CT scan. MRI is helpful in staging the extent and spread of pancreatic carcinoma rather than for detecting tumors or lesions less than 2 cm in size. MRI scan while determining pancreatic adenocarcinoma relies on the assessment of the size, shape, contour of the gland. MRI is helpful in characterizing cystic lesions of the pancreas and can aid in arriving at the diagnosis. MRI scan of the pancreas while assesing for pancreatic cancer presents as hypointense on T1-weighted images and hyperintense or isointense on T2-weighted images. During dynamic MR imaging, the tumor of pancreatic cancer in the early phase shows diminished enhancement and in the late phase shows gradual enhancement.

MRI

MRI: [1] [2][3][4]

  • MRI is considered when there is a diagnostic difficulty even after performing a CT scan.
  • MRI is helpful in staging the extent and spread of pancreatic carcinoma rather than for detecting tumors or lesions less than 2 cm in size.
  • MRI also helps in avoiding the radiation exposure when compared to a CT scan.
  • MRI scan while determining pancreatic adenocarcinoma relies on the assessment of the size, shape, contour of the gland.
  • Gadolinium is the contrast material most commonly used in the contrast MRI scan of the pancreas.
  • MRI is helpful in characterizing cystic lesions of the pancreas and can aid in arriving at the diagnosis.
  • Pancreatic cancer shows hypointense lesions on gadolinium-enhanced T1-weighted images.
  • For the complete evaluation of the pancreatic parenchyma and the pancreaticobiliary ductal system, the following magnetic resonance sequences is advised:
    • T1-weighted gradient-echo; T2-weighted axial and coronal sequences, usually turbo spin-echo; two dimensional (2D) and three dimensional (3D) MRCP
    • T1-weighted 3D gradient-echo (GRE) before and after intravenous administration of gadolinium.
  • Diffusion-weighted imaging (DWI) nowadays is being widely used.
  • MRI scan of the pancreas while assesing for pancreatic cancer presents as:[5] [6]
    • Hypointense on T1-weighted images
    • Hyperintense or isointense on T2-weighted images.
    • During dynamic MR imaging, the tumor of pancreatic cancer in the early phase shows diminished enhancement and in the late phase shows gradual enhancement.

References

  1. Tummala P, Junaidi O, Agarwal B (2011). "Imaging of pancreatic cancer: An overview". J Gastrointest Oncol. 2 (3): 168–74. doi:10.3978/j.issn.2078-6891.2011.036. PMC 3397617. PMID 22811847.
  2. Lee ES, Lee JM (2014). "Imaging diagnosis of pancreatic cancer: a state-of-the-art review". World J Gastroenterol. 20 (24): 7864–77. doi:10.3748/wjg.v20.i24.7864. PMC 4069314. PMID 24976723.
  3. Sahani DV, Bonaffini PA, Catalano OA, Guimaraes AR, Blake MA (2012). "State-of-the-art PET/CT of the pancreas: current role and emerging indications". Radiographics. 32 (4): 1133–58, discussion 1158-60. doi:10.1148/rg.324115143. PMID 22786999.
  4. Schima W (2006). "MRI of the pancreas: tumours and tumour-simulating processes". Cancer Imaging. 6: 199–203. doi:10.1102/1470-7330.2006.0035. PMC 1766565. PMID 17208676.
  5. Gabata T, Matsui O, Kadoya M, Yoshikawa J, Miyayama S, Takashima T; et al. (1994). "Small pancreatic adenocarcinomas: efficacy of MR imaging with fat suppression and gadolinium enhancement". Radiology. 193 (3): 683–8. doi:10.1148/radiology.193.3.7972808. PMID 7972808.
  6. Vellet AD, Romano W, Bach DB, Passi RB, Taves DH, Munk PL (1992). "Adenocarcinoma of the pancreatic ducts: comparative evaluation with CT and MR imaging at 1.5 T." Radiology. 183 (1): 87–95. doi:10.1148/radiology.183.1.1312736. PMID 1312736.